<![CDATA[Biotek-snakken — September 2022]]>Børsen:
Novo Nordisk har købt det amerikanske biotekselskab Forma Therapeutics for en pris på 1,1 mia. dollar (8,2 mia. kr.), skriver selskabet i en børsmeddelelse.

]]>https://dev.proinvestor.com/forum/topic/401423/biotek-snakken-september-2022RSS for NodeSat, 06 Jun 2026 13:18:19 GMTThu, 01 Sep 2022 11:05:20 GMT60<![CDATA[Reply to Biotek-snakken — September 2022 on Fri, 30 Sep 2022 05:08:28 GMT]]>Spændende aktie...

]]>https://dev.proinvestor.com/forum/post/8065032https://dev.proinvestor.com/forum/post/8065032Fri, 30 Sep 2022 05:08:28 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Fri, 30 Sep 2022 02:54:26 GMT]]>Tak for genopfriskning @ Havneholmen. Desværre ikke til at se på kursen endnu. 😉

]]>https://dev.proinvestor.com/forum/post/8065031https://dev.proinvestor.com/forum/post/8065031Fri, 30 Sep 2022 02:54:26 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Fri, 30 Sep 2022 02:29:38 GMT]]>Ascelia Pharma med gode data i andet support studie også

]]>https://dev.proinvestor.com/forum/post/8065033https://dev.proinvestor.com/forum/post/8065033Fri, 30 Sep 2022 02:29:38 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Fri, 30 Sep 2022 02:29:19 GMT]]>
Link Preview Image
Ascelia Pharma Announces Successful Final Results from Orviglance Hepatic Impairment Study – ASCELIA

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announce ...

favicon

(www.ascelia.com)

]]>https://dev.proinvestor.com/forum/post/8065029https://dev.proinvestor.com/forum/post/8065029Fri, 30 Sep 2022 02:29:19 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Thu, 29 Sep 2022 02:24:15 GMT]]>Godmorgen...

]]>https://dev.proinvestor.com/forum/post/8065024https://dev.proinvestor.com/forum/post/8065024Thu, 29 Sep 2022 02:24:15 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Wed, 28 Sep 2022 11:11:32 GMT]]>Jep...

]]>https://dev.proinvestor.com/forum/post/8065030https://dev.proinvestor.com/forum/post/8065030Wed, 28 Sep 2022 11:11:32 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Wed, 28 Sep 2022 11:04:04 GMT]]>Ja, du glemte bare at linke. 😉

]]>https://dev.proinvestor.com/forum/post/8065027https://dev.proinvestor.com/forum/post/8065027Wed, 28 Sep 2022 11:04:04 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Wed, 28 Sep 2022 10:59:12 GMT]]>Tak bibob. Den var den jeg hentyde til i Bavarian chatten...

]]>https://dev.proinvestor.com/forum/post/8065022https://dev.proinvestor.com/forum/post/8065022Wed, 28 Sep 2022 10:59:12 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Wed, 28 Sep 2022 10:52:40 GMT]]>Ascelia Pharma. https://storage.mfn.se/ac898d08-02ba-4233-a962-7b1b78562b13/ascelia-pharma-announces-successful-final-results-from-orviglance-hepatic-impairment-study.pdf

]]>https://dev.proinvestor.com/forum/post/8065023https://dev.proinvestor.com/forum/post/8065023Wed, 28 Sep 2022 10:52:40 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Fri, 23 Sep 2022 13:45:33 GMT]]>Enligt Xbrane Biopharmas styrelseordförande Anders Tullgren ska bolaget bli kassaflödespositiva i det fjärde kvartalet 2023 eller det första kvartalet 2024, vilket är ett upprepat mål.

]]>https://dev.proinvestor.com/forum/post/8065021https://dev.proinvestor.com/forum/post/8065021Fri, 23 Sep 2022 13:45:33 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Fri, 23 Sep 2022 13:21:26 GMT]]>Biosimilarutvecklaren Xbrane Biopharmas partner kring Ximluci (ranibizumab) i Europa, Stada Arzneimittel, befinner sig i partnerskapsdiskussioner för utvalda marknader i Asien.
Det sade Bryan Kim, chef för specialistprodukter vid Stada Arzneimittel, under Xbrane Biopharmas kapitalmarknadsdag på torsdag.

När Nyhetsbyrån Direkt ställde frågan om vilka asiatiska länder Bryan Kim ser som intressanta nämnde han Korea och Vietnam.

]]>https://dev.proinvestor.com/forum/post/8065020https://dev.proinvestor.com/forum/post/8065020Fri, 23 Sep 2022 13:21:26 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Thu, 22 Sep 2022 11:38:50 GMT]]>Novavax's sku lidt af en nedjustering JP Morgan er kommet med fra 132 USD til 27 USD vildt uprofessionelt at de kan skyde så meget med sprede hagl

]]>https://dev.proinvestor.com/forum/post/8065026https://dev.proinvestor.com/forum/post/8065026Thu, 22 Sep 2022 11:38:50 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Mon, 19 Sep 2022 06:52:48 GMT]]>ja veloxis tjente jeg en god million på men ligenu venter jeg mere på Hansa får succes og gang i salget før jeg vil ud i noget andet

]]>https://dev.proinvestor.com/forum/post/8065028https://dev.proinvestor.com/forum/post/8065028Mon, 19 Sep 2022 06:52:48 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Mon, 19 Sep 2022 06:20:34 GMT]]>Jeg var også så heldig, at være med i Veloxis - Det var et eventyr.

]]>https://dev.proinvestor.com/forum/post/8065025https://dev.proinvestor.com/forum/post/8065025Mon, 19 Sep 2022 06:20:34 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Mon, 19 Sep 2022 06:19:54 GMT]]>Meget spændende firma, som jeg har aktier i Helge...

]]>https://dev.proinvestor.com/forum/post/8065014https://dev.proinvestor.com/forum/post/8065014Mon, 19 Sep 2022 06:19:54 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Sun, 18 Sep 2022 10:16:46 GMT]]>Ascelia Pharma - et nyt Veloxis eventyr? https://www.proinvestor.com/boards/106180

]]>https://dev.proinvestor.com/forum/post/8065016https://dev.proinvestor.com/forum/post/8065016Sun, 18 Sep 2022 10:16:46 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Sun, 18 Sep 2022 03:10:51 GMT]]>2 Biotech Stocks That Could Make You Richer https://www.proinvestor.com/investornyt/880059/2-biotech-stocks-that-could-make-you-richer

]]>https://dev.proinvestor.com/forum/post/8065018https://dev.proinvestor.com/forum/post/8065018Sun, 18 Sep 2022 03:10:51 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Fri, 16 Sep 2022 09:36:06 GMT]]>Enig Jazz….den skal holdes….ligger godt i mit langsigtede pensions depot….Tænker den vil klare sig godt i et recessions marked, så er helt tryg ved den, selvom udsvingene er lidt voldsomme indimellem 🙂

]]>https://dev.proinvestor.com/forum/post/8065017https://dev.proinvestor.com/forum/post/8065017Fri, 16 Sep 2022 09:36:06 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Fri, 16 Sep 2022 09:29:27 GMT]]>Dejligt med STADA som trofast partner: In July 2018, STADA and Xbrane entered into an agreement under which the two companies are jointly responsible for development until regulatory approval and for manufacturing the finished product. STADA will hold the marketing authorizations and the commercial rights to the biosimilar across all territories included in the agreement, which covers Europe, the US, several countries in the Middle East and North Africa (MENA) region, and several Asia-Pacific (A

]]>https://dev.proinvestor.com/forum/post/8065012https://dev.proinvestor.com/forum/post/8065012Fri, 16 Sep 2022 09:29:27 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Fri, 16 Sep 2022 09:25:52 GMT]]>Som du selv siger. Casen bliver hele tiden lidt bedre.. så skidt med at der er udskiftning i aktie ejere med nogle der måske er lidt mere langsigtet. Vi er long term i Xbrane.. kurs 350-500 i 2026

]]>https://dev.proinvestor.com/forum/post/8065019https://dev.proinvestor.com/forum/post/8065019Fri, 16 Sep 2022 09:25:52 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Fri, 16 Sep 2022 09:12:26 GMT]]>Hele nyheden: European Medicines Agency’s CHMP adopts positive opinion for Ximluci® biosimilar candidate referencing Lucentis® (ranibizumab). Positive opinion proposes authorization of Ximluci® throughout EU. STADA CEO Peter Goldschmidt: “This positive opinion reflects STADA’s ongoing expansion of its biosimilars portfolio within Specialty Care, as well STADA Specialty Care’s https://xbrane.com/en/mfn_news/stada-and-xbrane-welcome-ema-positive-opinion-for-ranibizumab-biosimilar-candidate-ximluci

]]>https://dev.proinvestor.com/forum/post/8065011https://dev.proinvestor.com/forum/post/8065011Fri, 16 Sep 2022 09:12:26 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Fri, 16 Sep 2022 08:56:43 GMT]]>Og den nyhed valgte IBKR Financial Services AG så lige at sælge 25k stk på ….så forsvandt den stigning 🙂 skørt

]]>https://dev.proinvestor.com/forum/post/8065009https://dev.proinvestor.com/forum/post/8065009Fri, 16 Sep 2022 08:56:43 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Fri, 16 Sep 2022 08:52:06 GMT]]>Casen bliver stærkere hele tiden….spændende selskab 🙂

]]>https://dev.proinvestor.com/forum/post/8065013https://dev.proinvestor.com/forum/post/8065013Fri, 16 Sep 2022 08:52:06 GMT<![CDATA[Reply to Biotek-snakken — September 2022 on Fri, 16 Sep 2022 08:45:54 GMT]]>Her er nyheden 🙂 Dejligt på en sur dag… Biosimilarutvecklaren Xbrane Biopharma har fått ett positivt utlåtande för Ximluci (ranibizumab) från den europiska läkemedelsmyndigheten EMA:s rådgivande kommitté CHMP (Committee for Medicinal Products for Human Use).
Det framgår av en uppdatering från läkemedelsmyndigheten EMA i samband med septembermötet för perioden 12-15 september.

]]>https://dev.proinvestor.com/forum/post/8065007https://dev.proinvestor.com/forum/post/8065007Fri, 16 Sep 2022 08:45:54 GMT